Mektovi (Binimetinib) is a kinase inhibitor used along with encorafenib, to treat patients with unresectable/metastatic melanoma with a mutation named BRAF V600E or V600K.
Dosage: The recommended binimetinib dose is 45 mg, administered orally twice daily, about 12 hours apart, along with drug encorafenib until the disease is progressive or in occurence of unacceptable toxicity. Binimetinib may be administered either with or without food. Do not take any missed dose of binimetinib within 6 hours of the next dose. Do not administer an additional dose in case vomiting occurs after administration of binimetinib dosage but carry on with the next scheduled dose.
Side Effects: The most commonly reported binimetinib side effects along with encorafenib
- Abdominal pain
Warnings and Precautions:
- It is recommended to confirm the presence of a BRAF V600E or V600K mutation in tumor specimens before starting binimetinib 15 mg therapy.
- Recipients with cardiovascular risk factors should be monitored closely while on mektovi dosage.
- Patients should be monitored for liver laboratory tests prior to the initiation of binimetinib 15 mg tablet, monthly during treatment.
- Monitor patients for CPK as well as creatinine levels before starting encorafenib-binimetinib, periodically during treatment.
- Findings indicate that the mektovi 15 mg can be responsible for causing fetal harm if administered to a pregnant woman.
- Due to the potential for serious side effects from encorafenib and binimetinib in breastfed infants, women should not breastfeed during therapy and for 3 days after the last dose.